The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | NKTR-255 in multiple myeloma and NHL
Nina Shah, MD, University of California, San Francisco, CA, presents preliminary findings from the Phase I trial (NCT04136756) of NKTR-255, a recombinant human interleukin (IL)-15 agonist, in patients with relapsed/refractory hematologic malignancies. NKTR-255 targets IL-15Rα receptors and were found to expand T-cells and natural killer (NK) cells in preclinical models. Patients generally tolerated the therapy, and NKTR-255 managed to increase IL-6 levels. Dr Shah additionally discusses potential its uses in non-Hodgkin lymphoma (NHL), or with rituximab in multiple myeloma. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
